加味扶正抑瘤汤辅助化疗对胰腺癌免疫功能、血清肿瘤标志物和不良反应的影响

黄虹超; 兰小容

doi:10.3969/j.issn.1671-038X.2021.10.09

加味扶正抑瘤汤辅助化疗对胰腺癌免疫功能、血清肿瘤标志物和不良反应的影响

黄虹超^,,
兰小容

- 德阳市人民医院肿瘤科(四川德阳, 618000)

详细信息

通讯作者: 黄虹超,E-mail:you_chao6@126.com

中图分类号: R735.9

收稿日期: 2021-05-26

Effect of modified Fuzheng Yiliu Decoction adjuvant chemotherapy on immune function,serum tumor markers and toxic and side effects of pancreatic cancer

HUANG Hongchao^,,
LAN Xiaorong

- Department of Oncology, Deyang People's Hospital, Deyang, 618000, China

More Information

Corresponding author: HUANG Hongchao, E-mail: you_chao6@126.com

Received Date: 26 May 2021

摘要

摘要: 目的:探究加味扶正抑瘤汤辅助化疗对胰腺癌免疫功能、血清肿瘤标志物和不良反应的影响。方法:选取2019年2月—2021年1月收治的62例胰腺癌患者作为研究对象,随机分为对照组和观察组,每组各31例。对照组采用吉西他滨化疗治疗方案,观察组在前者化疗方案基础上联用加味扶正抑瘤汤。比较2组治疗8周后疗效;比较2组治疗前及治疗8周后中医症状积分、免疫功能(CD3⁺、CD4⁺、CD4⁺/CD8⁺)、血清肿瘤标志物[糖类抗原19-9(CA19-9)、糖类抗原125(CA125)、糖类抗原242(CA242)、癌胚抗原(CEA)]、生命质量[胰腺癌患者生存质量特异量表(QLQ-PAN-26)评分];比较2组治疗后3个月内不良反应发生情况。结果:治疗8周后,观察组总缓解率显著高于对照组(P<0.05);2组中医症状积分、CA19-9、CA125、CA242、CEA均有所下降(P<0.05),观察组降幅较对照组更显著(P<0.05);观察组QLQ-PAN-26评分有所下降(P<0.05),亦低于对照组(P<0.05);观察组CD3⁺、CD4⁺、CD4⁺/CD8⁺较治疗前有所下降(P<0.05),但高于对照组(P<0.05)。治疗后3个月内,观察组不良反应总发生率为19.34%,显著低于对照组的45.16%(P<0.05)。结论:加味扶正抑瘤汤辅助化疗有助于胰腺癌患者症候改善及调节免疫功能,使肿瘤标志物水平得到一定调控,减少化疗不良反应,从而促进患者生命质量改善,临床应用价值较高。
- 加味扶正抑瘤汤 /
- 化疗 /
- 胰腺癌 /
- 免疫功能 /
- 血清肿瘤标志物 /
- 不良反应
Abstract: Objective: To explore the effect of modified Fuzheng Yiliu Decoction adjuvant chemotherapy on immune function, serum tumor markers and toxic and side effects of pancreatic cancer.Methods: A total of 62 patients with pancreatic cancer from February 2019 to January 2021 were selected as the subjects of this study, and they were randomly divided into a control group and an observation group with 31 cases in each group. The control group was treated with gemcitabine chemotherapy, and the observation group was combined with modified Fuzheng Yiliu Decoction on the basis of chemotherapy regimen in the former group. The efficacy of the two groups was compared after 8 w of treatment, and the scores of TCM symptoms, immune function(CD3⁺,CD4⁺,CD4⁺/CD8⁺), serum tumor markers[carbohydrate antigen 19-9(CA19-9), carbohydrate antigen 125(CA125), carbohydrate antigen 242(CA242), carcinoembryonic antigen(CEA) ]and quality of life[quality of life scale of patients with pancreatic cancer(QLQ-PAN-26) ]were compared between the two groups before treatment and after 8 w of treatment. Toxic and side effects in the two groups were compared within 3 months after treatment.Results: After 8 w of treatment, the total remission rate of observation group was significantly higher than that of control group(P<0.05). The TCM symptoms scores, CA19-9, CA125, CA242 and CEA of the two groups were significantly decreased compared with those before treatment(P<0.05), and the above indicators of observation group were significantly lower than those of control group at the same period(P<0.05). The QLQ-PAN-26 scores of observation group were significantly reduced compared to before treatment(P<0.05), and were significantly lower than those of control group(P<0.05). The CD3⁺,CD4⁺,CD4⁺/CD8⁺in observation group were significantly increased compared with those before treatment(P<0.05), and were significantly higher than those in control group(P<0.05). Within 3 months after treatment, the total incidence rate of toxic and side effects of 19.34% in observation group was significantly lower than 45.16% in control group(P<0.05).Conclusion: Modified Fuzheng Yiliu Decoction adjuvant chemotherapy can effectively improve the immune function and control the levels of serum tumor markers of patients with pancreatic cancer, and reduce the symptoms, promote the improvement of quality of life, and reduce the toxic and side effects of chemotherapy, with a high clinical application value.
- modified Fuzheng Yiliu Decoction /
- chemotherapy /
- pancreatic cancer /
- immune function /
- serum tumor markers /
- toxic and side effects

HTML全文

参考文献(25)

[1]	施思,虞先濬.新辅助治疗对胰腺癌围手术期并发症的影响[J].中华医学杂志,2021,101(10):708-711.
[2]	Collisson EA,Bailey P,Chang DK,et al.Molecular subtypes of pancreatic cancer[J].Nat Rev Gastroenterol Hepatol,2019,16(4):207-220.
[3]	McGuigan A,Kelly P,Turkington RC,et al.Pancreatic cancer:A review of clinical diagnosis,epidemiology,treatment and outcomes[J].World J Gastroenterol,2018,24(43):4846-4861.
[4]	Loveday BPT,Lipton L,Thomson BN.Pancreatic cancer:An update on diagnosis and management[J].Aust J Gen Pract,2019,48(12):826-831.
[5]	樊高飞,王成,张腾跃,等.维拉帕米联合化疗药物介入治疗中晚期胰腺癌的疗效研究[J].中国中西医结合消化杂志,2019,27(9):643-648.
[6]	贺艳平,田志红,底卫东.动脉优先入路胰十二指肠切除术联合吉西他滨治疗胰腺癌的效果分析[J].中国临床实用医学,2019,10(1):39-41.
[7]	杨旭初,吕会艳,王怀璋,等.益气化瘀汤合沙参麦冬汤辅助化疗对气阴两虚型肺癌患者肿瘤控制率及机体状况的影响[J].实用药物与临床,2021,24(1):38-42.
[8]	赵琦琦,朱涵榆.扶正健脾消积汤与FOLFOX4化疗方案联合治疗晚期结肠癌的临床观察[J].中国中医药科技,2021,28(1):120-121.
[9]	郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:241-245.
[10]	中国抗癌协会胰腺癌专业委员会.胰腺癌综合诊治指南(2018版)[J].临床肝胆病杂志,2018,34(10):2109-2120.
[11]	王陇德.临床诊疗指南肿瘤分册[M].北京:人民卫生出版社,2011:405-406.
[12]	贾林,尚鸳鸳,江舒曼,等.胰腺癌患者抑郁症状与生存质量的关系[J].中华医学杂志,2009,89(26):1847-1849.
[13]	Liu YJ,Zhu GP,Guan XY.Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma[J].Oral Oncol,2012,48(6):554-559.
[14]	董祖木.六君子汤合益胃汤联合化疗治疗晚期胃癌临床观察[J].贵州医药,2021,45(6):903-904.
[15]	杨露银,杨忠明.治疗宫颈癌的六君子汤主要活性成分和关键靶点基因筛选及生物学功能分析[J].山东医药,2021,61(18):39-43.
[16]	王子恺,周文丽,李闻,等.消化道微生态与胰腺疾病[J].中国微生态学杂志,2019,31(10):1232-1235.
[17]	张冰,朱国玲,孙秋,等.基线空腹血糖水平与急性胰腺炎发病风险的前瞻性队列研究[J].中国全科医学,2021,24(1):60-64.
[18]	侯巧梅,孟敏.联合检测被转化生长因子b激活的长链非编码RNA和糖链抗原19-9对胰腺癌的诊断和预后价值[J].安徽医药,2021,25(1):127-131.
[19]	Hegde S,Krisnawan VE,Herzog BH,et al.Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer[J].Cancer Cell,2020,37(3):289-307.
[20]	Yamamoto K,Venida A,Yano J,et al.Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I[J].Nature,2020,581(7806):100-105.
[21]	李树颖,秦雪梅,李科.黄芪多糖免疫调节作用及其机制研究进展[J].山西医科大学学报,2019,50(5):685-689.
[22]	顾思浩,孔维崧,张彤,等.白术的化学成分与药理作用及复方临床应用进展[J].中华中医药学刊,2020,38(1):69-73.
[23]	张珂,陈素梅,邓清华,等.重楼抗肿瘤作用的分子机制研究进展[J].浙江临床医学,2017,19(2):369-371.
[24]	罗球珠,李穗晖,黄楚燕.莪术醇的分离鉴定及体外抗肿瘤作用机制研究[J].中国药业,2021,30(2):38-41.
[25]	黄晓伟,安红梅,胡兵.现代解毒抗癌中药治疗大肠癌研究进展[J].环球中医药,2018,11(11):1838-1842.